دانلود مقالات ISI درباره Pasi 90 + ترجمه فارسی

ایمنی و کارآیی درازمدت اتانرپت در کودکان و نوجوانان مبتلا به پسوریازیس پلاک

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

Keywords: etanercept; long-term safety; open-label; pediatric population; plaque psoriasis; AE; adverse event; CDC; Centers for Disease Control and Prevention; FDA; Food and Drug Administration; HRQOL; health-related quality of life; JIA; juvenile idiopathic arthri

دانلود رایگان متن کامل مقاله ISI 11 صفحه سال انتشار : 2016 سفارش ترجمه

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Keywords: anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPASI-1; CIMPASI-2; phase 3 trial; CZP; certolizumab pegol; DLQI; Dermatology Life Quality Index; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index;

دانلود رایگان متن کامل مقاله ISI 35 صفحه سال انتشار : 2018 سفارش ترجمه

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

Keywords: anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPACT; etanercept; phase 3 trial; CZP; certolizumab pegol; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index; PASI 50; ≥50% reduction in PASI from

دانلود رایگان متن کامل مقاله ISI 36 صفحه سال انتشار : 2018 سفارش ترجمه

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-

Keywords: adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; f-PGA; Fingernail Physician Global Assessment; HRQoL; health-relate

دانلود رایگان متن کامل مقاله ISI 13 صفحه سال انتشار : 2017 سفارش ترجمه

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Keywords: psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As

دانلود رایگان متن کامل مقاله ISI 19 صفحه سال انتشار : 2017 سفارش ترجمه

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Keywords: clear or almost clear skin; clinical trial; head to head; plaque psoriasis; secukinumab; superiority; ustekinumab; 90% or more improvement in baseline Psoriasis Area and Severity Index; AE; adverse event; DLQI; Dermatology Life Quality Index; HRQoL; healt

دانلود رایگان متن کامل مقاله ISI 10 صفحه سال انتشار : 2015 سفارش ترجمه

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Keywords: adolescent; biologic; children; pediatric; psoriasis; systemic therapy; ustekinumab; AE; adverse event; CDLQI; Children's Dermatology Life Quality Index; HRQoL; health-related quality of life; HSD; half-standard dose; PASI; Psoriasis Area and Severity Ind

دانلود رایگان متن کامل مقاله ISI 10 صفحه سال انتشار : 2015 سفارش ترجمه

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Keywords: clinical trial; dosing; immunogenicity; noninferiority; psoriasis; retreatment as needed; secukinumab; AE; adverse event; DLQI; Dermatology Life Quality Index; IGA; investigator global assessment; PASI; Psoriasis Area and Severity Index; PASI 75; 75% or m

دانلود رایگان متن کامل مقاله ISI 11 صفحه سال انتشار : 2015 سفارش ترجمه

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Keywords: Histology; IL-23; gene expression; guselkumab; psoriasis; Psoriasis Area and Severity Index; serum; skin; T cell; TH17; AE; Adverse event; DC; Dendritic cell; IL-12Rβ1; IL-12 receptor β1; IL-23R; IL-23 receptor; KRT16; Keratin 16; LCN2; Lipocalin 2; PAS

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2014 سفارش ترجمه

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

Keywords: adalimumab; anti-tumor necrosis factor therapy; clinical trial; efficacy; long-term treatment; open-label; psoriasis; safety; AE; adverse events; eow; every other week; LOCF; last observation carried forward; OLE; open-label extension; PASI; Psoriasis A

دانلود رایگان متن کامل مقاله ISI 11 صفحه سال انتشار : 2012 سفارش ترجمه

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

Keywords: ALT; alanine aminotransferase; AST; aspartate aminotransferase; ANOVA; analysis of variance; BSA; body surface area; DLQI; Dermatology Life Quality Index; EXPRESS; European Infliximab for Psoriasis (Remicade) Efficacy and Safety Study; EXPRESS II; Evaluat

دانلود رایگان متن کامل مقاله ISI 15 صفحه سال انتشار : 2007 سفارش ترجمه